Glucagon-like peptide-1 (GLP-1) Agonists 2023 Review Test
Glucagon-like peptide-1 (GLP-1) Agonists 2023 Review Test Indication for Glucagon-like peptide-1 (GLP-1) agonists - ANS-Type 2 diabetes, (used to increase insulin release) Adverse drug reactions to Glucagon-like peptide-1 (GLP-1) agonists - ANS-diarrhea, nausea, vomiting, constipation Glucagon-like peptide-1 (GLP-1) agonist suffixes - ANS--glu/tide Exenatide (Byetta®) - ANS-Glucagon-like peptide-1 (GLP-1) agonist Exenatide extended-release (Bydureon®) - ANS-Glucagon-like peptide-1 (GLP-1) agonist Liraglutide (Victoza®) - ANS-Glucagon-like peptide-1 (GLP-1) agonist Dulaglutide (Trulicity®) - ANS-Glucagon-like peptide-1 (GLP-1) agonist Semaglutide (Ozempic®, Rybelsus®) - ANS-Glucagon-like peptide-1 (GLP-1) agonist Note: GLP-1 agonists come as subcutaneous injections that must be stored refrigerated (except Rybelsus®, which is an oral tablet form of semaglutide)
Written for
- Institution
- Glucagon-like peptide-1 Agonists 2023 Rev
- Course
- Glucagon-like peptide-1 Agonists 2023 Rev
Document information
- Uploaded on
- October 7, 2023
- Number of pages
- 1
- Written in
- 2023/2024
- Type
- Exam (elaborations)
- Contains
- Questions & answers
Also available in package deal